Generating the Evidence to Support Stereotactic Radiotherapy Evolution: Challenges and a Roadmap for Progress
International Journal of Radiation Oncology*Biology*Physics · 2026
DOI: 10.1016/j.ijrobp.2026.01.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Timothy P Hanna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Queen's University, Kingston, Ontario, Canada. Electronic address: tim.hanna@kingstonhsc.ca. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Evidence-Based Medicine, Neoplasms, Radiation Oncology. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Queen's University.
Abstract (Originalsprache)
Cancer treatment evolves, often under the selective pressures of clinical trials. Although some indications in radiation oncology are fading, new possibilities are emerging. Phase III randomized controlled trials remain the most immediate and influential drivers of evolution, sometimes changing practice overnight. Yet radiation oncology has increasingly struggled to keep pace in this sector. There are several important reasons why practice-defining phase III trials for stereotactic radiation therapy (SRT) (and for radiation oncology more broadly) are not being conducted as often as they should be. These headwinds include: (1) funding challenges and regulatory burdens; (2) phase III bypass and loss of equipoise; (3) nonaligned endpoints and patient-centered outcomes; and (4) value, equity, and opportunity costs. Corresponding solutions must be based on (1) diversified funding models; (2) more efficient trial designs; (3) patient-centered outcome priorities; and (4) consensus on evidence standards for funding and adoption. The continued evolution of SRT will require deliberate investment and collaboration, with an emphasis on robust, rigorous, patient-centered evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Oncology, Queen's University, Kingston, Ontario, Canada. Electronic address: tim.hanna@kingstonhsc.ca.
- Department of Oncology, Western University, London, Ontario Canada.
- Department of Oncology, Queen's University, Kingston, Ontario, Canada.
- Department of Radiation Oncology, University of Texas Southwestern, Dallas, Texas.
- The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.
- Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
Förderung
- Queen's University
Zitieren
APA
Hanna, T. P., Palma, D. A., Booth, C. M., Sanford, N. N., Tree, A., & Yom, S. S. (2026). Generating the Evidence to Support Stereotactic Radiotherapy Evolution: Challenges and a Roadmap for Progress. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.01.024
Vancouver
Hanna TP, Palma DA, Booth CM, Sanford NN, Tree A, Yom SS. Generating the Evidence to Support Stereotactic Radiotherapy Evolution: Challenges and a Roadmap for Progress. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.01.024
BibTeX
@article{Hanna2026,
author = {Hanna, Timothy P and Palma, David A and Booth, Christopher M and Sanford, Nina N and Tree, Alison and Yom, Sue S},
title = {Generating the Evidence to Support Stereotactic Radiotherapy Evolution: Challenges and a Roadmap for Progress},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
doi = {10.1016/j.ijrobp.2026.01.024}
}
EUVIMED